DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hope for kids with rare brain tumors
Disease control Recruiting nowThis study tests the drug lorlatinib in children (ages 1 to 21) with a newly diagnosed high-grade glioma that has a specific genetic change (ALK or ROS1 fusion). The goal is to see if the drug can shrink or control the tumor and to check its safety when given with or after other …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: EARLY_PHASE1 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 17, 2026 10:43 UTC
-
New hope for kids with DIPG: major trial launches
Disease control Recruiting nowThis phase 3 trial tests whether the drug ONC201 works better than everolimus for children with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. About 433 participants will be randomly assigned to one of the two drugs, and if their disease gets worse, t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3K27-ALTERED
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 15, 2026 11:54 UTC